Full-Time
Medical Secretary 3
Gastroenterology/Biliary
Updated on 9/13/2026
Wash U
Academic research and entrepreneurial institution
Compensation Overview
$19.29 - $29.91/hr
St. Louis, MO, USA
Hybrid
Mandatory in-person training and some mandatory in-person meetings; office visits are required to pick up supplies as needed.
Associate's
 Medical, Clinical & Veterinary (1) |
|---|
- A high school diploma or equivalent high school certification, or a combination of education and experience.
- Three years of experience in a medical office setting.
- Substantial use of medical terminology is required for advanced secretarial duties.
- An Associate degree is preferred.
- Preferred skills include communication, decision making, medical terminology, Microsoft Office, software packages, and working independently.
- Transcribe medical documents such as physician’s letters, correspondence, nurse’s notes, and manuscripts; complete electronic medical record requisitions and orders per WashU guidelines when order entry is part of the job function.
- Maintain the physician’s daily appointment schedule and calendar, schedule meetings, arrange conference calls, reserve catering services, make travel arrangements, and complete travel expense reports.
- Schedule appointments and procedures for patients.
- Prepare patient charts, including delivering workups.
- Greet visitors, answer the telephone, take messages, and screen patient inquiries while providing information according to departmental procedures and policies.
- Serve as a liaison between patients, physicians, and staff by providing routine information in response to patient inquiries.
- Assist administrative and clinical staff during peak times and during vacations or illnesses.
- Assist with the retrieval and delivery of reports, films, and other materials.
- Provide float coverage and perform other duties as assigned.
Wash U translates academic research into practical technologies and programs that address global challenges. The institution supports scholars through grants and partnerships to move discoveries from the lab into the public sector via entrepreneurship and technology transfer. Unlike many traditional research institutions, Wash U emphasizes a high level of financial transparency and leverages a historical connection to Nobel Laureates to foster a collaborative environment. Its goal is to use these shared visions and research initiatives to create a more equitable future and provide tangible benefits to society.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
1853
Simplify's Take
What believers are saying
- WashU Medicine’s NIH portfolio remains the second largest among U.S. medical schools.
- WashU and Bristol Myers Squibb fund three translational neuroscience programs annually.
- WashU research keeps converting into licenses and FDA-relevant devices, including Neuraptive and stroke tools.
What critics are saying
- Washington University laid off 316 staff and cut 198 roles in 2025.
- Federal research funding cuts and a projected $37 million endowment tax strain budgets.
- If NIH dollars weaken further, WashU loses research scale and top-faculty retention.
What makes Wash U unique
- WashU Medicine and BJC Health named Philip Payne chief health AI officer in 2026.
- WashU and Bristol Myers Squibb launched a 2026 neuroscience collaboration with trainee embeds.
- WashU licensed a bioresorbable nerve stimulator to Neuraptive Therapeutics in July 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Company Match
Wellness Program
Mental Health Support
Parental Leave
Family Planning Benefits
Company News
WashU Medicine marketing and communications wins five Telly Awards. August 28, 2026 A movie trailer, local TV spot and documentaries produced by WashU Medicine Marketing & Communications recently won five Telly awards, an international contest honoring excellence in TV and video production. The 47th annual competition recognizes creators, brands and production companies from national television networks, movie studios, major brands, sports teams and universities, among others. The organization received nearly 14,000 entries, a 6% increase from last year and the most ever. And the awards go to... * "In Our Lifetime - Part 1: A Piece of Me" follows a family burdened by inherited early-onset Alzheimer's disease and the hope they find in research led by WashU Medicine. The documentary received a silver award in the category Branded Content - Documentary: Short Form (Under 40 minutes). The team included (cinematographer and editor) Huy Mach, WashU Medicine senior video producer; (producer) Macallan Lay, project manager; (director) Josh Kell, assistant vice chancellor and executive creative director; and Jessica Church, director of media relations. * "Changing What's Possible" is a powerful, 30-second look into WashU Medicine's approach to advancing medicine. The commercial received a silver award in the Local TV Craft Writing category. Recipients were Jessy Lobel, senior creative director, and Kell. * "The Cure Within" documents the first patients in the region to receive a newly approved gene therapy for sickle cell disease and the WashU Medicine physicians who made the opportunity possible. The video won two bronze medals in the categories Branded Content - Documentary: Short Form (Under 40 minutes) and Branded Content - Science & Technology. Staff members involved were Mach, Kell, Church and senior sciences writer Marta Wegorzewska. * "Another Tomorrow" features patients whose lives were transformed by a drug for a genetic form of amyotrophic lateral sclerosis (ALS). Research led by WashU Medicine served as the basis for the drug's FDA approval. The trailer received a bronze in the category Film & Shorts - Movie Trailer. Winners were Mach, Lay, Kell and Church.
A painless punch with a microneedle patch could detect kidney disease earlier. Kidney disease is silent in its early stages, progressing without symptoms until the disease is advanced. Researchers in the McKelvey School of Engineering at Washington University in St. Louis, in collaboration with researchers at WashU Medicine and at Texas A&M University, have been developing a minimally invasive method to improve diagnosis in earlier stages. New research from the lab of Srikanth Singamaneni, the Lilyan & E. Lisle Hughes Professor in the Department of Mechanical Engineering & Materials Science, shows the early success of a microneedle patch that can be applied on the skin to quickly and safely capture biomarkers and quantify them accurately. The patch detected early signs of kidney injury and may one day support home or point-of-care monitoring without requiring refrigeration. Results of their research were published online Aug. 5 in Advanced Materials. It is the first study to show that encapsulating biomolecules on microneedles preserved their biological functions. The research team, which includes Yixuan Wang, a doctoral student in Singamaneni's lab, created microneedles coated with a metal-organic framework (MOF) that can sample interstitial fluid in the skin. The microneedles are coated with a material that creates a shell that detects and preserves neutrophil gelatinase-associated lipocalin (NGAL) antibodies, which are an early biomarker of acute kidney injury. The MOF shell preserved the antibodies for up to four weeks at 50 C (122 F) without refrigeration. "This metal-organic framework encapsulation is a simple and highly effective way to create microneedle sensors that are resilient to environmental challenges and provide a scalable path to minimally invasive biosensing for at-home or remote health monitoring," Singamaneni said. NGAL increases in the blood within hours of a kidney injury and is a clinically validated biomarker for kidney damage. However, because it requires drawing blood with a needle and cold-chain logistics, it has not been useful in home-based or resource-limited settings. Previously, Singamaneni and collaborators established another type of microneedle patches that can look for biomarkers of disease. Adapting that low-cost, easy-to-use technology required them to create a biosensor with high sensitivity and a broader range, as well as addressing cold-chain logistics. Wang Y, Liu Y, Debnath A, Li C, Want Z, Kondepati G, Balmoori S, Morrissey JJ, Chen YM, Tian L, Singamaneni S. Metal-Organic Framework-Preserved Thermostable Microneedle Patch for Minimally Invasive Detection and Monitoring of Kidney Dysfunction. Advanced Materials, published online Aug. 5, 2026. DOI: https://doi.org/10.1002/adma.74423 This research was supported by funding from the National Science Foundation (CBET 2224610 and CBET 560 2316285), the National Institutes of Health (R21DK131557A1, R35 GM147568, R01 2DK105056-6 and R56DK138158A1), the Congressionally Directed Medical Research Programs (HT94252310996 and W81XWH-19-1-0320), and VA Merit (I01BX006401A1). Singamaneni and Jeremiah J. Morrissey are the inventors of the plasmonic-fluor technology, which has been licensed by the Office of Technology Management at Washington University in St. Louis.
WashU Medicine honors CEO Haruo Naito and Eisai for longstanding contributions to Alzheimer's disease research and healthcare. August 18, 2026 Eisai Co., Ltd. (Headquarters: Tokyo, "Eisai") announced today that Washington University School of Medicine in St. Louis ("WashU Medicine") held a ceremony unveiling a plaque honoring the longstanding contributions and achievements of CEO Haruo Naito and Eisai in healthcare, including in the field of Alzheimer's disease (AD). The plaque, commemorating these achievements, will be permanently displayed on a wall in the lobby of the Jeffrey T. Fort Neuroscience Research Building (NRB). CEO Haruo Naito and Eisai were recognized for their long-term and significant contributions to WashU Medicine and the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), as well as for the profound impact CEO Naito's leadership and vision have had on patients, families and researchers around the world. Eisai and WashU Medicine have been collaborating in research on neurodegenerative diseases, including dementia and Parkinson's disease. In particular, in the AD field, the Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicine, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody etalanetug (E2814) for the treatment of dominantly inherited Alzheimer's disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab was selected as the backbone anti-amyloid therapy. The collaboration between WashU Medicine neuroscience researchers and Eisai reinforces a shared mission of advancing human healthcare, which accelerates turning discoveries from medical research into solutions for patients, improving care for families today while working toward a future free of neurodegenerative disease. Media contacts: Public Relations Department, Eisai Co., Ltd.
WashU Medicine appoints new chief of Head and Neck Surgery. By Siteman Communications Published: August 13, 2026 | Updated: August 13, 2026 Read time: 3 mins Andrés M. Bur, MD, FACS, a nationally known oncologist and reconstructive surgeon, will also co-lead the Head and Neck Tumor Center at Siteman Cancer Center Andrés M. Bur, MD, FACS, has been named chief of the Division of Head and Neck Surgery in the Department of Otolaryngology - Head & Neck Surgery at WashU Medicine and co-director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. He will co-lead the Head and Neck Tumor Center at Siteman alongside fellow directors and WashU Medicine physicians Douglas R. Adkins, MD, a medical oncologist, and Wade L. Thorstad, MD, a radiation oncologist. Bur begins his new roles Oct. 22. As a nationally recognized head and neck surgical oncologist and reconstructive surgeon, Bur has built an outstanding academic program centered on precision oncology, artificial intelligence (AI), machine learning, radiomics and translational head and neck cancer research, said Sid Puram, MD, PhD, FACS, the head of the Department of Otolaryngology - Head & Neck Surgery and the Lindburg Professor of Otolaryngology at WashU Medicine. Puram, who was appointed head of Otolaryngology - Head & Neck Surgery at WashU Medicine in October, previously served as co-director of the Head and Neck Tumor Center at Siteman. "Dr. Bur's work has advanced the application of AI to surgical decision-making, imaging, outcomes prediction and clinical workflow while maintaining a strong emphasis on improving patient outcomes through multidisciplinary cancer care," Puram said. "His track record is one of surgical innovation, multidisciplinary cancer care, mentorship of trainees and translational research." Bur joins WashU Medicine and Siteman Cancer Center from the University of Kansas School of Medicine, where he has served as the David S. Zamierowski Professor, vice chair of research, vice chair of Innovation and Technology in the Department of Otolaryngology-Head and Neck Surgery and director of Minimally Invasive and Robotic Head and Neck Surgery. "I look forward to partnering with the remarkable faculty, staff and, above all, patients at WashU Medicine and Siteman Cancer Center," he said. "By delivering exceptional care and driving innovation, we are collectively building the future of otolaryngology." Bur earned his bachelor's degree in electrical engineering summa cum laude from Tufts University and his medical degree from the University of Pennsylvania. He completed his residency in otolaryngology-head and neck surgery at the University of Pennsylvania before completing fellowship training in head and neck oncologic and reconstructive surgery at Emory University. He co-chairs the American Head and Neck Society Artificial Intelligence Task Force, where he leads strategic planning, educational programming and policy guidelines for AI adoption. He has also led numerous investigations and published in such leading head and neck journals as JAMA Otolaryngology-Head & Neck Surgery, Head & Neck, Oral Oncology, JAMA Network Open and The Laryngoscope. Bur is also deeply committed to education and mentorship and has overseen fellow recruitment, curriculum development and national training standards while mentoring the next generation of academic surgeons. Nationally, he serves as chair of the American Head and Neck Society Young Members Service, reflecting his commitment to leadership development and advancing the specialty.
Lee and Lee honored with prestigious Cogan Award. August 7, 2026 Aaron Y. Lee, MD, the Arthur W. Stickle Distinguished Professor of Ophthalmology and Visual Sciences and head of the John F. Hardesty, MD Department of Ophthalmology & Visual Sciences at WashU Medicine, and Cecilia Lee, MD, the Jane Hardesty Poole Distinguished Professor, have been honored with the Cogan Award in recognition of their impactful contributions to vision science and ophthalmic research. This prestigious award, presented by the Association for Research in Vision and Ophthalmology (ARVO), highlights exceptional work that propels the field forward through innovative methods and collaborative leadership. Their recognition underscores WashU Medicine's leadership in combining clinical excellence, innovative research and collaborative science to address some of the most challenging questions in vision care. Lee and Lee harness large-scale data, machine learning and advanced analytics to elucidate complex patterns in eye disease and vision loss, while also leveraging the eye as a non-invasive window into systemic health - a field known as oculomics. Their research emphasizes equitable access to data and analytic tools, ensuring that discoveries benefit diverse populations and accelerate real-world translational impact.